Product Code: ETC6192659 | Publication Date: Sep 2024 | Updated Date: May 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Temporal arteritis, also known as giant cell arteritis, is an inflammatory condition affecting the blood vessels, often leading to vision loss if untreated. The Australia temporal arteritis market is driven by the aging population, as the condition predominantly affects individuals over the age of 50. Treatments for temporal arteritis typically involve corticosteroids, and there is increasing interest in the development of new, more targeted therapies to prevent complications. The growing awareness of this condition and the advancement of diagnostic techniques are expected to contribute to the markets expansion in the coming years.
The temporal arteritis market in Australia is driven by an aging population, as this condition primarily affects individuals over 50 years of age. Temporal arteritis is characterized by inflammation of the arteries in the head, leading to headaches, vision problems, and even stroke in severe cases. The treatment market for this condition includes corticosteroids as the primary therapy, with new therapies such as biologic drugs also emerging as potential options. As the awareness of temporal arteritis grows, especially among healthcare professionals, the demand for effective treatments is expected to rise, alongside improved diagnostic tools that enable early detection of this potentially debilitating condition.
The Temporal Arteritis Market in Australia faces the challenge of underdiagnosis, as the condition often goes unnoticed or is mistaken for other common ailments. As a result, many individuals experience delayed treatment, leading to more severe complications. Furthermore, there is limited awareness about this condition among the general population, leading to lower demand for specialized treatments. The cost of treatments, especially for those requiring long-term medication or surgical interventions, is another challenge that limits access for some patients.
While a niche segment, the temporal arteritis market presents investment opportunities in early diagnosis and treatment technologies, including imaging tools, biomarkers, and targeted drug development. As the condition primarily affects older adults, there`s potential for integrated care solutions combining diagnostics, pharmaceuticals, and long-term monitoring systems that can attract healthcare and biotech investors.
Temporal arteritis treatment in Australia falls under the broader healthcare policy framework, particularly Medicare and the PBS, which subsidize diagnostic tests and immunosuppressive medications. The TGA governs the safety and distribution of corticosteroids and related drugs used in treatment. Policies promoting early diagnosis of autoimmune conditions also support increased screening and awareness among general practitioners and rheumatologists.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Temporal Arteritis Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Temporal Arteritis Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Temporal Arteritis Market - Industry Life Cycle |
3.4 Australia Temporal Arteritis Market - Porter's Five Forces |
3.5 Australia Temporal Arteritis Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 Australia Temporal Arteritis Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Australia Temporal Arteritis Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 Australia Temporal Arteritis Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Temporal Arteritis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Temporal Arteritis Market Trends |
6 Australia Temporal Arteritis Market, By Types |
6.1 Australia Temporal Arteritis Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 Australia Temporal Arteritis Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 Australia Temporal Arteritis Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.1.4 Australia Temporal Arteritis Market Revenues & Volume, By Aristocort, 2021- 2031F |
6.1.5 Australia Temporal Arteritis Market Revenues & Volume, By Bubbli-Pred, 2021- 2031F |
6.1.6 Australia Temporal Arteritis Market Revenues & Volume, By Immunosuppressive Agents, 2021- 2031F |
6.1.7 Australia Temporal Arteritis Market Revenues & Volume, By Adalimumab, 2021- 2031F |
6.1.8 Australia Temporal Arteritis Market Revenues & Volume, By Infliximab, 2021- 2031F |
6.2 Australia Temporal Arteritis Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Australia Temporal Arteritis Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Australia Temporal Arteritis Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3 Australia Temporal Arteritis Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Australia Temporal Arteritis Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Australia Temporal Arteritis Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.4 Australia Temporal Arteritis Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.5 Australia Temporal Arteritis Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Temporal Arteritis Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Australia Temporal Arteritis Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Australia Temporal Arteritis Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.4 Australia Temporal Arteritis Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 Australia Temporal Arteritis Market Import-Export Trade Statistics |
7.1 Australia Temporal Arteritis Market Export to Major Countries |
7.2 Australia Temporal Arteritis Market Imports from Major Countries |
8 Australia Temporal Arteritis Market Key Performance Indicators |
9 Australia Temporal Arteritis Market - Opportunity Assessment |
9.1 Australia Temporal Arteritis Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 Australia Temporal Arteritis Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Australia Temporal Arteritis Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 Australia Temporal Arteritis Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Temporal Arteritis Market - Competitive Landscape |
10.1 Australia Temporal Arteritis Market Revenue Share, By Companies, 2024 |
10.2 Australia Temporal Arteritis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |